Other languages Landos Biopharma, Inc.

Equities

LABP

US5150692011

Market Closed - Nasdaq Other stock markets 02:00:00 01/05/2024 am IST			5-day change	1st Jan Change
22.3 ^USD	-0.80%		+0.68%	+509.29%

02/04	North American Morning Briefing : Stocks Seen -2-	DJ
01/04	HC Wainwright Downgrades Landos Biopharma to Neutral From Buy	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Deals of the day-Mergers and acquisitions	26/03
Sector Update: Health Care Stocks Decline Late Afternoon	26/03
Top Midday Gainers	25/03
Sector Update: Health Care Stocks Softer in Afternoon Trading	25/03
AbbVie to Acquire Landos Biopharma For About $137.5 Million; Landos Shares Jump	25/03
AbbVie to Acquire Landos Biopharma for About $137.5 Million	25/03
AbbVie to buy Landos to expand pipeline of immunity-related illnesses	25/03
Landos Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Landos Biopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Landos Biopharma, Inc. Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn?s and Colitis	21/11
Landos Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Landos Biopharma to Present At the American College of Gastroenterology 2023 Annual Scientific Meeting	23/23/23
Landos Biopharma, Inc. Announces Resignation of Patrick Truesdell as Principal Accounting Officer, Patrick Truesdell Remain with Company Until November 10, 2023	21/23/21
Landos Biopharma Enters Research Collaboration to Investigate Effects of NX-13 on Epithelial Cells	14/23/14
Landos Biopharma, Inc. Announces Strategic Research Collaboration with Ku Leuven and University Hospitals Leuven to Further Characterize the Effects of Nx-13 on Epithelial Cells	14/23/14
Landos Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09
Landos Biopharma, Inc. Appoints Alka Batycky to its Board of Directors and Audit Committee	31/23/31
Landos Biopharma to Implement 1-for-10 Reverse Stock Split	26/23/26
Landos Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12
Wall Street Set to Open Higher; April Jobs Report Tops Expectations	05/23/05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Landos Biopharma, Inc.

Equities

LABP

US5150692011

Other languages

Filters